BrainParrot

Union Health Ministry Proposes Immediate Suspension of Manufacturing Licences for Drugs Found Not of Standard Quality on Specified Critical Parameters

GS2Full notePublished: · Updated:

Source: PIB (Press Information Bureau) · Read the original ↗

Summary

  • The Health Ministry has proposed amendments to the Drugs Rules, 1945. Under them, the licensing authority would immediately suspend a drug's manufacturing licence once a Government Analyst declares it Not of Standard Quality (NSQ) on specified critical parameters.
  • At present, suspension or cancellation follows a show-cause procedure, leaving a time gap in which substandard drugs stay in the market.
  • The draft rules are open for public consultation for 30 days.

UPSC relevance: GS2 – Governance/Health: regulation, drug quality; GS2 – Social Justice: health

Key facts for Prelims

  • Instrument: amendment to the Drugs Rules, 1945 (under the Drugs and Cosmetics Act, 1940).
  • NSQ = Not of Standard Quality. Immediate suspension is triggered only by a Government Analyst's report that declares NSQ on one of five specified critical parameters:
  • Assay
  • Dissolution
  • Related Substances
  • Impurities
  • Sterility
  • Authority that suspends: the Central Licensing Approving Authority or the State Licensing Authority, as the case may be.
  • Conditions for revocation:
  • The manufacturer undertakes an effective Root Cause Analysis (RCA).
  • It implements Corrective and Preventive Action (CAPA) to the licensing authority's satisfaction.
  • The authority verifies the CAPA.
  • Form 13 (Government Analyst's test report) is also being amended. The report will be endorsed to the DCGI, the State/UT Licensing Authority with jurisdiction over the manufacturing site, and the manufacturer and marketer.
  • Process: draft notification → public consultation → final rules.

Data and details

  • Public consultation window: 30 days from the date copies of the Gazette of India with the draft rules are made available to the public.
  • Comments go to: Under Secretary (Drugs), Ministry of Health & Family Welfare, Kartavya Bhawan-1, New Delhi – 110001 (email: drugsdiv-mohfw[at]gov[dot]in).
  • Background deliberations: the 65th meeting of the DCC (20 December 2024) and recommendations of the 92nd meeting of the DTAB (24 April 2025).
  • Existing situation, per the release: suspension or cancellation is preceded by regulatory procedure including a show-cause notice. This creates a gap between an NSQ declaration and action, during which the drug may stay in circulation, making recall harder.
  • Expected benefits: stronger post-marketing surveillance, timely action, greater manufacturer and marketer accountability, and public confidence.

Static–dynamic linkage

  • The Drugs and Cosmetics Act, 1940 regulates the import, manufacture, sale and distribution of drugs. The Drugs Rules, 1945 are the delegated legislation that operationalises it. The Centre amends them through a draft notification → public consultation → final notification process.
  • Drug regulation is shared: the Centre (CDSCO/DCGI) approves new drugs and imports, while State Licensing Authorities license manufacturing and sale. That makes quick coordination between regulators a governance question.
  • The news shifts the model from a notice-first approach to a suspend-first approach on defined, high-risk quality failures. The aim is patient safety through a faster regulatory response.

Syllabus mapping: GS2 – Governance/Social Justice: health regulation; statutory and regulatory bodies; GS2 – Polity: delegated legislation (rule-making under a parent Act).

Background primer

Drugs and Cosmetics Act, 1940 / Drugs Rules, 1945

What it is:
The principal Central law on drug quality and safety, with its rules.
Founded:
Act of 1940 and Rules of 1945 (standard background).
Members:
Enforced by Central and State Licensing Authorities and Government Analysts. Advisory bodies are the DTAB and DCC (below).
Mandate:
Licensing of manufacture and sale, standards of quality and testing. The Act's "standards of quality" are those set out in its Second Schedule.
Why it matters:
Prevent substandard, spurious and misbranded drugs reaching patients.

Drugs Technical Advisory Board (DTAB) and Drugs Consultative Committee (DCC)

What it is:
Two advisory bodies under the Act. DTAB advises the Central and State Governments on technical matters arising from the Act's administration. DCC advises the Centre, States and DTAB on securing uniformity throughout India in administering the Act.
Founded:
DTAB is constituted under Section 5 of the Act, and DCC under Section 7 (both set up by the Central Government).
Members:
DTAB: the Director General of Health Services is ex officio Chairman. DCC: two representatives of the Central Government and one from each State Government.
Mandate:
CDSCO's DTAB-DCC division initiates amendments to the Drugs Rules on DTAB's recommendations and coordinates with the Ministry on draft and final Gazette notifications. DCC meetings are held under the Drugs Controller General (India).
Why it matters:
Technical, expert and federal inputs before rules change.

Not of Standard Quality (NSQ) drugs

Additional context

  • Good Manufacturing Practices: The Centre amended the Drugs Rules, 1945 by G.S.R. 922(E) dated 28.12.2023 to revise Schedule M (GMP and premises/plant requirements). The revised Schedule M became effective from 28.06.2024 for large manufacturers (turnover above Rs 250 crore). Small and medium manufacturers (turnover Rs 250 crore or less) were conditionally given time up to 31.12.2025. The NSQ-suspension proposal adds an enforcement step on top of this.

Mains dimensions

  • Closing the response gap: The key change is timing. Action starts when the Government Analyst's report is received, not after a show-cause process. This reduces the window in which a substandard batch can circulate.
  • Targeted, proportionate design: Only five critical parameters trigger automatic suspension. Other NSQ failures stay under the existing procedure, which limits the risk of over-penalising minor deviations.
  • Accountability across the chain: Form 13 endorsement to DCGI, the State regulator, the manufacturer and the marketer means the marketer is also informed.
  • Quality system, not only punishment: Revocation depends on RCA and CAPA, which pushes firms to fix systemic faults.
  • Federal coordination: Both Central and State licensing authorities can suspend, so success depends on State regulatory capacity, lab testing speed and consistent application.
  • Due-process concern: Suspension without a prior hearing may draw challenge on natural-justice grounds. Safeguards such as quick verification and an appeal route are likely to matter.
  • Public health and trade: Quality assurance protects patients and also India's credibility as a major supplier of medicines.

Possible Mains question

**GS2, 10 marks:** "The Health Ministry has proposed immediate suspension of manufacturing licences for drugs found NSQ on critical parameters. Discuss how this strengthens drug regulation and what challenges may arise in implementation."

Related topics

  • Drugs and Cosmetics Act, 1940; CDSCO, DCGI; Schedule M (GMP)
  • New Drugs and Clinical Trials Rules, 2019; Medical Devices Rules, 2017
  • Delegated legislation and natural justice (audi alteram partem)
  • Right to Health (Art. 21), Directive Principles (Arts. 39, 47); Centre–State roles in health regulation

Topics: GS2

How we write and check these notes →

All current affairs of 4 November 2026 → · UPSC Current Affairs